Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [2][5]. Group 1: Allegations Against Agilon Health - The complaint alleges that agilon health and its executives made false and misleading statements regarding the company's financial guidance for 2025, which they knew was unattainable due to industry challenges [5]. - It is claimed that the company overstated the financial benefits from strategic actions taken to mitigate risks, leading to materially false representations about its business and prospects [5]. - Following the release of disappointing second-quarter results on August 4, 2025, agilon health's stock plummeted by 51.5% the next day, indicating significant investor losses [6]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased agilon health securities between February 26, 2025, and August 4, 2025, are encouraged to discuss their legal rights and options, with a deadline of March 2, 2026, to seek the role of lead plaintiff in the class action [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest in the case, who will oversee the litigation on behalf of the class [7]. - Faruqi & Faruqi, LLP is also seeking information from whistleblowers, former employees, and shareholders regarding agilon health's conduct [8].

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. due to allegations of misleading statements regarding its Phase 3 PALISADE-3 trial for fasedienol, which did not meet its primary endpoint [1][2][3]. Group 1: Lawsuit Details - The lawsuit, Dan Eller v. Vistagen Therapeutics, Inc., was initiated in the United States District Court for the Northern District of California [1]. - The complaint alleges that Vistagen provided overly positive statements while concealing material adverse facts about the Phase 3 trial of fasedienol [2]. Group 2: Trial Results - On December 17, 2025, Vistagen announced that the PALISADE-3 Phase 3 study did not show a statistically significant improvement on the primary endpoint, with no treatment difference between fasedienol and placebo for secondary endpoints [3]. Group 3: Stock Price Impact - Following the announcement of the trial results, Vistagen's stock price plummeted from $4.36 per share on December 16, 2025, to $0.86 per share on December 17, 2025, marking a decline of over 80% [4]. Group 4: Legal Representation - Levi & Korsinsky, LLP, the law firm representing the plaintiffs, has a strong track record in securities litigation and encourages affected shareholders to step forward before the March 16, 2026 deadline [4][5].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its drug nimacimab during the class period from November 4, 2024, to October 3, 2025 [7]. Allegation Details - The lawsuit claims that Skye's management misrepresented the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [7]. - Specific allegations include that nimacimab was less effective than claimed, leading to misleading public statements about its potential [7]. Stock Impact - Following the announcement of disappointing clinical trial results on October 6, 2025, Skye's stock price dropped by $2.85 per share, or 60%, closing at $1.90 per share [7]. Next Steps - Investors who purchased Skye securities during the class period and suffered losses are encouraged to contact Bragar Eagel & Squire for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 16, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in securities litigation [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].

Core Viewpoint - Varonis Systems, Inc. is facing a federal securities class action due to allegations of misleading statements regarding its business performance and growth potential, particularly in its transition to a SaaS model [5][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating potential claims against Varonis and has set a deadline of March 9, 2026, for investors to seek the role of lead plaintiff in the class action [2]. - The complaint alleges that Varonis and its executives made false and misleading statements about the company's ability to convert its customer base, which led to inflated stock prices [5]. Group 2: Financial Performance and Stock Impact - On October 28, 2025, Varonis reported third-quarter results that significantly missed its Annual Recurring Revenue (ARR) targets and lowered its full-year guidance due to weaker renewals and conversions [6]. - Following the announcement, Varonis' stock price plummeted from $63.00 to $32.34 per share, marking a decline of approximately 48.67% in just one day [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Vanda Pharmaceuticals Inc. is under investigation for potential violations of federal securities laws following a significant stock price drop due to FDA's decision on its drug application for HETLIOZ® [1][2]. Group 1: Company News - Vanda Pharmaceuticals announced on January 8, 2026, that the FDA's CDER concluded that the supplemental New Drug Application (sNDA) for HETLIOZ® for treating jet lag disorder cannot be approved in its current form [2]. - The FDA acknowledged positive efficacy from Vanda's clinical trials but determined that the evidence was insufficient for effectiveness in treating jet lag disorder, citing that the trial protocols did not adequately simulate actual jet travel conditions [2]. - Following the FDA's announcement, Vanda's stock price fell over 14% on January 8, 2026 [2]. Group 2: Legal and Investigation - Levi & Korsinsky has commenced an investigation into Vanda Pharmaceuticals regarding potential violations of federal securities laws, inviting investors who suffered losses to explore recovery options [1][3].

Core Insights - Holzer & Holzer, LLC is investigating whether Corcept Therapeutics Incorporated complied with federal securities laws following the issuance of a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for relacorilant [1] - The announcement led to a decline in Corcept's stock price, indicating potential investor concerns about the company's regulatory challenges [1] Company Overview - Corcept Therapeutics is focused on developing treatments for patients with conditions related to hypercortisolism, specifically hypertension [1] - The company is publicly traded on NASDAQ under the ticker symbol CORT [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Viewpoint - A class action lawsuit has been filed against Fermi, Inc. for allegedly making materially false and misleading statements regarding its business operations and prospects, particularly concerning the Project Matador campus [3][8]. Allegation Details - The lawsuit claims that Fermi overstated tenant demand for its Project Matador campus [3] - It is alleged that the company did not adequately disclose its reliance on a single tenant's funding commitment for the project's financing [3] - There is a significant risk that the tenant may terminate its funding commitment, which was not disclosed [3] - As a result, the positive statements made by the defendants about the company's business were misleading and lacked a reasonable basis [3] Next Steps - Investors who purchased Fermi shares and suffered losses can contact the law firm for more information and to discuss their legal rights [4][8] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is March 6, 2026 [8]

Core Viewpoint - Duluth Holdings Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price after lowering its sales guidance for Q3 2025 [1][2]. Financial Performance - Duluth Holdings announced its Q3 2025 financial results on December 16, 2025, revising its net sales guidance to a range of $555 million to $565 million, down from the previous guidance of $570 million to $595 million [2]. - The announcement led to a stock price decline of over 29% on the same day [2]. Legal Investigation - Levi & Korsinsky has initiated an investigation into Duluth Holdings regarding potential securities law violations, inviting affected investors to explore recovery options [1][3].

Core Viewpoint - A class action lawsuit has been filed against StubHub Holdings, Inc. on behalf of investors who acquired StubHub securities during the specified class period, particularly related to the company's September 2025 IPO [1][2]. Group 1: Lawsuit Details - The lawsuit claims that StubHub's IPO Registration Statement did not disclose significant changes in the timing of payments to vendors, which adversely affected the company's free cash flow [3]. - Investors who purchased StubHub securities during the class period have until January 23, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Overview - StubHub, based in New York, operates a digital ticketing marketplace for various live event categories globally [2]. - Berger Montague, the law firm representing the plaintiffs, is recognized for its expertise in complex civil litigation and has recovered over $50 billion for clients over its 55-year history [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Klarna To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Klarna pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Klarna’s September 2025 initial public offering (the “IPO”) and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wi ...